Skip to content

Reversal of vecuronium-induced moderate neuromuscular blockade by sugammadex in elder patients: pharmacokinetics, efficacy, and safety analyses

Reversal of vecuronium-induced moderate neuromuscular blockade by sugammadex in elder patients: pharmacokinetics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091903
Enrollment
Unknown
Registered
2024-11-05
Start date
2024-11-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal function

Interventions

adult group(A Group):Intravenous anesthesia was used for induction and maintenance of anesthesia, and i.v. vecuronium 0.12mg/kg was used for induction of neuromuscular block. At the TOF ratio appeared
Elder group(E Group):Intravenous anesthesia was used for induction and maintenance of anesthesia, and i.v. vecuronium 0.12mg/kg was used for induction of neuromuscular block. At the TOF ratio appeared

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Patients not undergoing emergency surgery scheduled for vicuronium under general anesthesia in the supine position; 2. Aged 18-74 years old, ASA classification I-II; 3.Voluntary participation in the study and signing patient informed consent

Exclusion criteria

Exclusion criteria: 1. Suffering from neuromuscular disease, liver dysfunction, heart disease and personal or family history of malignant hyperthermia, with moderate to severe renal impairment(CLCR=60ml/min); 2. Pregnant or breastfeeding women; 3. Difficult airway, sleep apnea syndrome and body mass index >= 28kg/m^2; 4. Patients who have taken the following drugs recently: aminoglycoside antibiotics, anticonvulsants, magnesium, and perioperative toremifene, fusidic acid and flucloxacillin.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters ;

Secondary

MeasureTime frame
time from administration of sugammadex to recovery of tof ratio to 0.7, 0.8 and 0.9;

Countries

China

Contacts

Public ContactTang Yiyang

Guangdong Provincial Hospital of Traditional Chinese Medicine

157769414@qq.com+86 137 5186 9517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026